Stiris Research Inc. Announces Database Lock in Phase II Hepatorenal-Syndrome Trial

London, ON — November 2nd, 2023 —

Stiris Research (“Stiris”) an entrepreneurial clinical trial management company focused on the management of Phase I-IIIB trials, announces the Database Lock in a Phase II study in Hepatorenal-Syndrome and Acute Kidney Injury (HRS-AKI).

“We are thrilled to reach this important milestone. Congratulations to all involved from start to finish in this trial – reaching database lock is a great culmination of efforts grounded in collaboration and a fantastic partnership with the trial team. We look forward to data analysis and are hopeful for positive results and positive outcomes for these patients.” Said Shantal Feltham, President & CEO

Hepatorenal syndrome (HRS) is a form of impaired kidney function that occurs in individuals with advanced liver disease. Individuals with hepatorenal syndrome do not have any identifiable cause of kidney dysfunction and the kidneys themselves are not structurally damaged. Blood circulation is abnormal in individuals with hepatorenal syndrome. The arteries that circulate oxygenated blood from the lungs to the rest of the body widen in contrast to the arteries of the kidney, which narrow causing a decrease in the blood flow through the kidney. (,themselves%20are%20not%20structural%20damaged.)

About Stiris Research

Stiris Research is an entrepreneurial Clinical Trial Management company specializing in conducting complex Phase I through IIIB trials for North American biotechnology and biopharmaceutical companies. Stiris Research was formed as a result of listening to the stakeholders engaged in clinical trials, identifying their unmet needs, and developing a unique, value-based approach to address those needs.

For more information, please contact:

Marketing – Stiris Research Inc.